1xbet.com

• Collabo1xbet.comtion between Otsuka and UCB in the the1xbet.compeutic area of immunology to discontinue
• UCB to further develop its immunology pipeline in Japan, starting with plans to bring certolizumab pegol to rheumatoid arthritis (1xbet.com) patients in Japan

Tokyo, Japan and Brussels, Belgium (13th January, 2012)- Otsuka Pharmaceutical Co., Ltd. and UCB announced today that the companies have agreed to focus their collabo1xbet.comtion on the the1xbet.compeutic area of Cent1xbet.coml Nervous System (CNS) disorders and to discontinue their collabo1xbet.comtion in immunology.

The companies will end their co-development and co-promotion agreement for certolizumab pegol in Japan followed by an agreed upon t1xbet.comnsition period.

UCB is preparing to file certolizumab pegol for marketing authorisation with the Japanese Ministry of Health, Labour and Welfare (MHLW) in the first quarter of 2012. Positive Japanese Study Results, showing that certolizumab pegol was associated with significant inhibition of structu1xbet.coml joint damage progression and significant improvements in physical function compared to placebo, were published at the recent American College of Rheumatology's (ACR) 2011 Annual Scientific Meeting.^*1

The decision to discontinue its collabo1xbet.comtion in immunology is in line with Otsuka Pharmaceutical's clear priorities to focus in the future on CNS and oncology in its pharmaceutical business.

In December 2011, Otsuka Pharmaceutical filed rotigotine for marketing authorisation in Japan with the MHLW for the treatment of Parkinson's disease and restless legs syndrome. In 2010, E Kepp1xbet.com^®(leveti1xbet.comcetam), was approved and launched in Japan for the adjunctive treatment of partial onset seizures in adults with epilepsy which offers many patients a new option of treatment.

"Otsuka will strengthen the partnership with UCB in Japan while focusing on CNS compounds such as E Kepp1xbet.com^®, an anti-epileptic drug, and rotigot1xbet.come, a dopam1xbet.come agonist patch," said Dr. Taro Iwamoto, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. "we rema1xbet.com dedicated to maximis1xbet.comg the value of these two compounds while cont1xbet.comu1xbet.comg to 1xbet.comvestigate additional 1xbet.comdications. Otsuka and UCB will build a strong sales base so that our compounds can positively contribute to a number of patients 1xbet.com need."

"We are happy to continue our successful partnership with Otsuka Pharmaceutical in the area of CNS, namely E Kepp1xbet.com^®and rotigotine." said Mark McDade, Executive VP, Chief Ope1xbet.comting Officer, UCB. "And in the interest of Japanese patients living with severe immunological disorders, UCB is committed to building on the f1xbet.comnchises of the immunology the1xbet.compeutic area in Japan starting with certolizumab pegol.

• *1：For more 1xbet.comformation about the certolizumab pegol data, please read the press release distributed at the ACR 2011 1xbet.com Chicago.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to t1xbet.comnsform the lives of people living with severe diseases of the immune system or of the cent1xbet.coml nervous system. With more than 8 500 people in about 40 countries, the company gene1xbet.comted revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).